Literature DB >> 8683905

Current topics in neuroleptic-induced extrapyramidal symptoms in Japan.

T Inada1, G Yagi.   

Abstract

This article reviews current topics in neuroleptic-induced extrapyramidal symptoms in Japan, focusing especially on the clinical features of akathisia and dystonia. Akathisia is a common side effect associated with antipsychotic drugs. It is most commonly characterized by subjective inner restlessness and objective motor signs, especially in the lower extremities. The mechanisms underlying akathisia remain unclear and controversial; however, an increase in the activity of beta-adrenergic systems relative to dopaminergic systems has been hypothesized, based on clinical therapeutic observations that beta-blocking agents are effective in this condition. A Japanese version of the Barnes Akathisia Scale has recently been established and uses a standardized videotape method for its precise evaluation. Various acute and chronic manifestations of neuroleptic-induced dystonia have been reported in Japan, including blepharospasm, difficulty in opening the eye lids, torticollis, retrocollis, oculogyric crisis, and Pisa syndrome. This review also introduces several other topics related to drug-induced extrapyramidal symptoms in Japan. These include; 1) the Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), which has recently been established, 2) studies on the discontinuation of anticholinergic drugs, and 3) a summary of extrapyramidal symptoms induced by drugs other than neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683905     DOI: 10.2302/kjm.45.95

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  5 in total

Review 1.  Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Taro Kishi; Nakao Iwata
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

2.  Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine.

Authors:  Taro Kishi; Shinji Matsunaga; Yuki Matsuda; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-10       Impact factor: 2.570

3.  Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Taro Kishi; Yuki Matsuda; Shinji Matsunaga; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-20       Impact factor: 2.570

4.  A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders.

Authors:  Taro Kishi; Yuki Matsuda; Shinji Matsunaga; Tomohiko Mukai; Masatsugu Moriwaki; Hideaki Tabuse; Kiyoshi Fujita; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-28       Impact factor: 2.570

5.  A Metabolomics Study of Serum in Hospitalized Patients With Chronic Schizophrenia.

Authors:  Naomichi Okamoto; Atsuko Ikenouchi; Keita Watanabe; Ryohei Igata; Rintaro Fujii; Reiji Yoshimura
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.